$XBI $90.61 | -4.3%
Covid Updates
$NVAX -3.6% Health Canada Authorizes Novavax COVID-19 Vaccine source
Pipeline Updates
$AGIO -5.2% Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency source
$GRCL -5.3% Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma source
$CLSN -4.0% Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer source
$VERU -4.3% Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium source
$PSTX -15.2% Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium source
$AZN +0.3% Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants source
$ARWR -8.3% Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022 source
$ALKS -5.4% Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium source
$EVLO -9.3% Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis source
$ENTA +2.4% ENANTA PHARMACEUTICALS ANNOUNCES PUBLICATION IN THE NEW ENGLAND JOURNAL OF MEDICINE OF DATA FROM THE PHASE 2A HUMAN CHALLENGE STUDY OF EDP-938 FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS (RSV) source
Business Updates
$SRNE -5.6% Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fortune Bioscience in Response to Increasing Worldwide Demand For COVISTIX™ source
Posted by JM
Comments